Current issues on the prophylaxis and the management of fungal infections in leukemic patients.
During the last few years, recent developments of the antifungal armamentarium have led to large studies on chemoprophylaxis as well as on new therapeutic regimen using new antifungal agents such as triazoles but also new modalities to administer amphotericin B. This progress, combined with increased awareness of clinicians about the high morbidity and mortality related to invasive fungal infection, suggests that there will be significant improvement of the prognosis for immunocompromised patients at risk of invasive fungal infections.